Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | GHSR | Q92847 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.43 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.43 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445226 | 0.91 | CTSD (0.48) | CCR1ABCB11ABCB1OPRK1GHSR | |
| SCHEMBL6443026 | 0.88 | UGT1A1 (0.47) | CCR1ABCB11ABCB1OPRK1GHSR | |
| SCHEMBL7395469 | 0.86 | CTSD (0.43) | CCR1ABCB11ABCB1OPRK1GHSR | |
| SCHEMBL6444048 | 0.86 | CYP3A4 (0.54) | CCR1ABCB11ABCB1OPRK1GHSR | |
| SCHEMBL6444044 | 0.86 | CYP3A4 (0.54) | CCR1ABCB11ABCB1OPRK1GHSR | |
| SCHEMBL6444499 | 0.85 | CCR1 (0.48) | CCR1ABCB11ABCB1OPRK1GHSR | |
| SCHEMBL6467572 | 0.84 | CTSD (0.41) | CCR1ABCB11ABCB1OPRK1GHSR | |
| SCHEMBL7290460 | 0.83 | UGT1A1 (0.46) | CCR1ABCB11ABCB1OPRK1GHSR | |
| SCHEMBL6429130 | 0.81 | CCR1 (0.52) | CCR1ABCB11ABCB1OPRK1GHSR | |
| SCHEMBL6447816 | 0.81 | CTSD (0.49) | CCR1ABCB11ABCB1OPRK1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CCR1 4439/4885ABCB11 3438/4885ABCB1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.